Condition: Diabetes Mellitus, Type 2 · Impaired Glucose Tolerance (IGT) · Impaired Fasting Glucose (IFG) · Sponsor: The University of Texas Health Science Center at San Antonio
HYPOTHESIS: Impaired glucose tolerance (IGT) and impaired fasting glucose (IFG) have distinct pathophysiologic etiologies. Therefore, therapeutic interventions designed to correct the specific underlying pathogenic abnormalities in IGT and IFG will be required to optimally prevent the progressive beta cell failure and development of overt type 2 diabetes.
This description comes directly from the study's public registry record.
Ralph A DeFronzo, MD · 210-567-6691 · defronzo@uthscsa.edu
Monica Palomo, BS · 210-567-6710 · palomom@uthscsa.edu
Always discuss trial participation with your own doctor first.
| The University of Texas Health Science Center at San Antonio | San Antonio, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT02969798